ClinicalTrials.gg
RecruitingNCT07212335MSC-ICAHTUpdated Oct 26, 2026

Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy

An Early Phase 1 interventional study of Mesenchymal Stem Cell Infusion in Immune Effector Cell Associated Hematotoxicity, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a single arm, open label, exploratory clinical study aimed at evaluating the efficacy, and safety of allogeneic umbilical cord blood-derived mesenchymal stem cells in the treatment of long-term cytopenia after CAR-T therapy.

Read the detailed description

This is a single-center, open-label, dose-escalation exploratory trial, whose primary objective is to evaluate the safety and preliminary efficacy of human umbilical cord-derived mesenchymal stem cell injection in patients with acute lymphoblastic leukemia, lymphoma, and multiple myeloma who still suffer from severe cytopenia 3 weeks after CAR-T infusion, so as to provide dose evidence and efficacy reference for subsequent studies.

Targeting the severe cytopenia complication with a high incidence rate (27%-95%) after CAR-T therapy and limited efficacy of conventional treatments, this trial adopts a "3+3" dose-escalation design. All three groups use a unified single dose of 2×10⁶ cells/kg body weight, differing only in infusion frequency (Group A: once; Group B: twice; Group C: four times), with 3 patients initially enrolled in each group. The dose-limiting toxicity (DLT) observation period is 28 days; if 2 or more DLTs occur, dose escalation will be terminated. The total sample size ranges from 15 to 24 cases, with a 24-week follow-up (weekly for the first 8 weeks and monthly from week 9 to week 24).

Cell Preparation: Dispensed according to the actual body weight of each subject at a standard dose of 2×10⁶ cells/kg body weight, in compliance with GMP requirements. The cell viability is ≥85%, and the preparation can only be released after passing pathogenic microorganism, purity and tumorigenicity screenings.

Infusion Procedure: Administer 5mg dexamethasone 30 minutes before infusion to prevent allergies. Thaw and mix the preparation at room temperature before infusion, with an initial rate of 20 drops/min for the first 15 minutes; if no discomfort occurs, adjust the rate to 40-60 drops/min (completing the infusion within 30-60 minutes). Monitor vital signs every 15 minutes during infusion and keep the patient under observation for 2 hours after infusion.

Safety: Graded according to NCI CTCAE 5.0. Acute reactions are monitored for 24 hours, delayed reactions are specifically examined at weeks 4, 8, 12 and 24, and serious adverse events (SAEs) must be reported within 24 hours.

Efficacy: Complete response (CR) and partial response (PR) require "dual-test compliance + 7 days without blood product transfusion" (with an interval of ≥48 hours). The response rate and duration are calculated at weeks 4 and 8 as key time points.

Immunological Detection: Collect samples at baseline and at weeks 1, 4 and 8 after infusion to detect inflammatory markers, immune cells and cytokines.

02

Conditions studied

  • Immune Effector Cell Associated Hematotoxicity

Browse trials for

Keywords

  • ICAHT
  • hematotoxicity
  • CAR-T
  • cytopenia
03

In context

Cytopenia

81 studies on the registry are indexed under Cytopenia; 25 are open to participants now.

This study's planned enrollment of 15 is below the median of 34 across 51 interventional studies indexed under Cytopenia.

Browse Cytopenia studies →

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all the following criteria to be enrolled in this study:

  • 1.Voluntarily participate in the study and sign the form;
  • 2.Aged ≥ 18 years, regardless of gender;
  • 3.Patients with acute lymphoblastic leukemia (ALL), lymphoma, or myeloma who still have severe cytopenia (meeting any of the following conditions: ≤ 1×10⁹/L; count ≤ 30×10⁹/L; ≤ 70 g/dL) 3 weeks after CAR-T cell infusion;
  • 4. performance status score ≤ 2;
  • 5.Estimated survival time ≥ 6 months;
  • 6.For female patients of , a negative pregnancy test result is required. Female patients of childbearing potential and male patients must use highly effective measures during the study period and for 4 months/6 months after the discontinuation of treatment, respectively.

Exclusion criteria

Exclusion Criteria

Patients with any of the following conditions are prohibited from enrolling in this study:

  • 1.Having received other anti-tumor treatments (including but not limited to chemotherapy, radiotherapy, targeted therapy, immunotherapy, or hematopoietic stem cell transplantation) that may affect the hematopoietic system or blood cell count within 1 month before the screening period after CAR-T cell infusion;
  • 2.Significant bone marrow infiltration by tumor cells during the screening period (for ALL: bone marrow morphological examination showing leukemia cell proportion > 5%; for multiple myeloma (MM) and lymphoma: bone marrow flow cytometry showing positive minimal residual disease (MRD), or bone marrow pathological immunohistochemistry showing lymphoma/clonal plasma cell infiltration);
  • 3.Presence of any of the following conditions within 1 week before the first dose administration: infection with hemodynamic instability (requiring vasoactive drug support); deep fungal infection confirmed by imaging or microbiology (e.g., invasive aspergillosis, bloodstream infection, etc.); Pneumocystis jirovecii pneumonia, active tuberculosis, viremia (cytomegalovirus, parvovirus B19, etc.), and viral pneumonia (cytomegalovirus, COVID-19 virus, influenza virus, adenovirus, parainfluenza virus, etc.); as well as other severe infections that may affect hematopoiesis as judged by the investigator;
  • 4.Serum creatinine or blood urea nitrogen ≥ 1.5 times the (ULN);
  • 5. (ALT) or aspartate aminotransferase (AST) ≥ 3 times ULN; total ≥ 1.5 times ULN;
  • 6.Other severe and/or uncontrolled diseases, or conditions that may affect study participation as judged by the investigator, including but not limited to: severe cardiac rhythm or conduction abnormalities (e.g., ventricular arrhythmias requiring clinical intervention, second-degree to third-degree atrioventricular block, etc.), interval using Fridericia's formula (QTcF) > 480 ms on ; (NYHA) heart function classification of Grade Ⅲ-Ⅳ; uncontrolled diabetes mellitus ( [HbA1c] > 9%); hypertension; ( [FEV1] \< 50% of predicted value), etc.;
  • 7.History of arteriovenous thrombosis or atherosclerosis;
  • 8.Positive for anti- (HIV) antibody or anti-Treponema pallidum specific antibody; positive for surface antigen (HBsAg); or positive for hepatitis B core antibody with hepatitis B virus deoxyribonucleic acid (HBV-DNA) > ULN; or virus ribonucleic acid (HCV-RNA) > ULN;
  • 9.A history of or current malignant solid tumor (except cured non-invasive basal cell or squamous cell carcinoma of the skin and/or other cured carcinoma in situ; except other malignant tumors that have achieved clinical cure for > 5 years with no recurrence within 5 years);
  • 10.Within 6 months after hematopoietic stem cell transplantation, or donor cell chimerism rate ≤ 95%, or presence of active acute (aGVHD) of Grade Ⅱ or higher, or moderate to severe chronic graft-versus-host disease (cGVHD);
  • 11.Having received a within 4 weeks before the first dose administration, or planning to receive any live vaccine during the study period;
  • 12.Pregnant or lactating female patients;
  • 13.Patients with mental disorders;
  • 14.Participation in any other study drug trial (including vaccine trials) or exposure to other study drugs within 4 weeks or 5 half-lives (whichever is longer) before the first dose administration;
  • 15.Patients who refuse to sign the form;
  • 16.Other conditions deemed unsuitable for study inclusion by the investigator.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    MSC

    Mesenchymal stem cells: intravenous infusion, 2×10⁶ cells/kg body weight/week (once weekly), with 1 to 4 administrations based on different dosage groups.

    Biological: Mesenchymal Stem Cell Infusion

Interventions

  • BiologicalMesenchymal Stem CellStudies of Mesenchymal Stem CellMesenchymal Stem Cell pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mesenchymal stem cells: intravenous infusion, 2×10⁶ cells/kg body weight/week (once weekly), with 1 to 4 administrations based on different dosage groups.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    Time frame: From recruitment to 24 weeks after the last treatment.

Secondary outcomes

  1. Complete Response (CR) rate

    Complete Response (CR) Criteria (no red blood cell/platelet transfusion for at least 7 days and meeting the standard in two consecutive tests): Hemoglobin (Hb) ≥ 100 g/L (for adults) or ≥ the lower limit of age-adjusted normal value; Absolute Neutrophil Count (ANC) ≥ 1.5×10⁹/L; Platelet Count (PLT) ≥ 100×10⁹/L.

    Time frame: At Week 4 and Week 8 after the completion of MSC infusion

  2. Partial Response (PR) rate

    Partial Response (PR) Criteria: Meeting any of the following conditions (no red blood cell/platelet transfusion for at least 7 days and meeting the standard in two consecutive tests): Neutrophils: Absolute value increased by ≥ 0.5×10⁹/L compared with the baseline; Platelets: Absolute value increased by ≥ 10×10⁹/L compared with the baseline; Hemoglobin: Absolute value increased by ≥ 15 g/L compared with the baseline.

    Time frame: At Week 4 and Week 8 after the completion of MSC infusion

  3. Overall Response (OR) rate

    OR=PR+CR

    Time frame: At Week 4 and Week 8 after the completion of MSC infusion

  4. Response time

    The median time from the first MSC infusion to the first achievement of CR/PR for various blood cell types.

    Time frame: From the first MSC infusion to 8th week after the last MSC infusion

  5. Duration of Relief(DOR)

    Time frame: from the date of achiving CR/PR to the earliest occurrence of hematopoietic indices falling below the CR/PR criteria or the end of the preset 24-week follow-up period after the first MSC infusion.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Researchers qualified can request the dataset, including de-identified individual subject data. Data may be requested from PI from 12 months to 36 months after study completion.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 12 months to 36 months after study completion

Access criteria: Upon request to PI

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 8, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07212335
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Oct 1, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Zhenzhen Wang
Contact
wangzhenzhen@ihcams.ac.cn
22-23608095

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesenchymal Stem Cell

Start the discussion